公开(公告)号：US10231950B2

公开(公告)日：2019-03-19

申请号：US15516031

申请日：2015-10-02

申请人： Convergence Pharmaceuticals Limited

发明人： Valerie Morisset

IPC分类号： A61K31/401 ,  C07D207/04 ,  C12Q1/6883

摘要： The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

公开(公告)号：US20170304265A1

公开(公告)日：2017-10-26

申请号：US15516121

申请日：2015-10-02

申请人： Convergence Pharmaceuticals Limited

发明人： Valerie Morisset

IPC分类号： A61K31/401 ,  C12Q1/68

摘要： The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

公开(公告)号：US20170290802A1

公开(公告)日：2017-10-12

申请号：US15516027

申请日：2015-10-02

申请人： Convergence Pharmaceuticals Limited

发明人： Valerie Morisset

IPC分类号： A61K31/401 ,  C12Q1/68

CPC分类号： A61K31/401 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

摘要： The present invention is directed to the treatment of small fibre neuropathy comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

公开(公告)号：US20170096708A1

公开(公告)日：2017-04-06

申请号：US15315991

申请日：2015-06-03

申请人： Convergence Pharmaceuticals Limited

发明人： Valerie Morisset

IPC分类号： C12Q1/68 ,  A61K31/40

CPC分类号： C12Q1/6883 ,  A61K31/40 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The invention relates to a method of diagnosing a paroxysmal pain disorder, such as trigeminal neuralgia, in a human subject and also provides a method of identifying patients most likely to respond to therapy and to kits for use in said methods.

公开(公告)号：US20200147041A1

公开(公告)日：2020-05-14

申请号：US16655921

申请日：2019-10-17

申请人： Convergence Pharmaceuticals Limited

发明人： Valerie Morisset

IPC分类号： A61K31/401 ,  C12Q1/6883

摘要： The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

公开(公告)号：US20190388391A1

公开(公告)日：2019-12-26

申请号：US16254251

申请日：2019-01-22

申请人： Convergence Pharmaceuticals Limited

发明人： Valerie Morisset

IPC分类号： A61K31/401 ,  C12Q1/6883 ,  C07D207/04

摘要： The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

公开(公告)号：US20170304264A1

公开(公告)日：2017-10-26

申请号：US15516031

申请日：2015-10-02

申请人： Convergence Pharmaceuticals Limited

发明人： Valerie Morisset

IPC分类号： A61K31/401 ,  C07D207/04 ,  C12Q1/68

CPC分类号： A61K31/401 ,  C07D207/04 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.